ARTICLE | Clinical News
Vion preclinical data
April 2, 2001 7:00 AM UTC
VION said data from a study in a lung carcinoma mouse model showed sub-optimal doses of ortho-3AP in combination with cytoxan cyclophosphamide yielded greater tumor growth inhibition compared to opti...